Drug

Study

ORR

mPFS

Reference

Atezolizumab

NCT02367794 (IMPower 131), N = 1021 (phase III), atezolizumab + chemotherapy vs. Placebo + chemotherapy

49.7% vs. 41%

6.3 vs. 5.6 mo.

Jotte et al. 2020 [18]

Atezolizumab

NCT02366143 (IMPower 150), N = 1202 (phase III), atezolizumab + bevacizumab + chemotherapy vs. Placebo + bevacizumab + chemotherapy

63.5% vs. 48.8%

8.3 vs. 6.8 mo.

Socinski et al. 2018 [19]

Pembrolizumab

NCT02775435 (Keynote-407), N = 559 (phase III), pembrolizumab + chemo-therapy vs. placebo + chemo-therapy (squamous)

57.9% vs. 38.4%

6.4 vs. 4.8 mo.

Paz-Ares et al. 2018 [20]

Pembrolizumab

NCT 02578680 (Keynote-189), N = 616 (phase III), pembrolizumab + chemotherapy vs. placebo + chemotherapy (adeno)

47.5% vs. 18.9%

8.8 vs. 4.9 mo.

Gandhi et al. 2018 [21]

Durvalumab

NCT03164616 (POSEIDON), N = 1013 (phase III), durvalumab + chemotherapy vs. chemotherapy

37.3% vs. 25.6%

5.5 vs. 4.8 mo.

Johnson et al. 2021 [22]